Bringing you the latest cutting-edge research and commentary in bioscience.

Cell & Gene Therapy Insights

Cell & Gene Therapy Insights

Interview

Building for future success: the Syncona Partners model

Martin Murphy


INVESTOR INSIGHTS


MARTIN MURPHY is Chief Executive Officer of Syncona Investment Management Ltd. He co-founded Syncona in 2012 with The Wellcome Trust. Since then, Martin has been closely involved in the foundation and development of five Syncona companies: Achilles, Autolus, Blue Earth, OMass and Quell Therapeutics. Previously, he was a partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcare, where he led their European operations. Martin has also held roles with 3i Group plc and McKinsey & Company. He has a PhD in Biochemistry from the University of Cambridge.

DOI: 10.18609/cgti.2020.003
Citation: Cell & Gene Therapy Insights2020; 6(1), 17–23
Open access
This content is restricted to registered users. Click here to Register or Login here.
Twitter IconVisit Our Blog